Trial Profile
A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2017
Price :
$35
*
At a glance
- Drugs Patidegib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Infinity Pharmaceuticals
- 19 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 19 Jun 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 19 Jun 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.